Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695237 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
NCT03695237 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 45 participants.
The verdict
NCT03695237, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the safety and efficacy of a leuprolide acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are either naïve to treatment with a gonadotropin-releasing hormone agonist (GnRHa) or who have been previously treated with a GnRHa.
Interventions
- DRUG Leuprolide Acetate (LA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2018-10-24 |
| Est. Completion | 2023-11-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03695237
The ClinicalTrials.gov registry entry for NCT03695237 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Leuprolide Acetate (LA) is the first listed.
NCT03695237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03695237 about?
NCT03695237 is a clinical study titled "A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)". The primary objective of the study is to assess the safety and efficacy of a leuprolide acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are either naïve to treatment with a gonadotropin-releasing hormone agonist (GnRHa) or who have been previously treated with a...
What is the current status of trial NCT03695237?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2018-10-24. Estimated completion is 2023-11-29.
What interventions are being tested in trial NCT03695237?
The interventions under investigation include: Leuprolide Acetate (LA) (DRUG).
Who is sponsoring clinical trial NCT03695237?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.